Loading…
Nervgen Pharma Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -16.9% over 5Y.
today you would have $1,031.91▲ +3.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.60 | $2.18 | $2.04 | $1.19 | |
| P/B | 59.5x | 128.3x | 59.5x | — | 5.2x |
| EPS | -$0.61 | -$0.36 | -$0.38 | -$0.39 | |
| ROE | -941.16% | -1268.86% | -941.16% | — | -153.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADAGAdagene Inc. | $3.68 | — | 2.8x | — | -28.50% | $247.09M |
| IPHAInnate Pharma SA | $2.22 | — | — | — | — | $247.97M |
| MGNXMacrogenics Inc | $3.80 | — | 5.6x | — | -225.85% | $242.06M |
| SIONSionna Therapeutics, Inc. | $5.51 |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Company description provided by Yahoo Finance.
| — |
| 0.9x |
| — |
| -32.34% |
| $249.12M |
| SYSo-Young International Inc. | $2.40 | — | 1.1x | — | -15.04% | $240.91M |
| PROFProfound Medical Corp. | $6.85 | — | 4.2x | — | -73.53% | $250.25M |